Thomas H Oguin 3rd
Overview
Explore the profile of Thomas H Oguin 3rd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
1696
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stover E, Rock M, Olson J, Schaaf G, Oguin 3rd T, Cline J, et al.
Radiat Res
. 2025 Mar;
PMID: 40048630
Acute total-body irradiation (TBI) leads to transient dose-dependent lymphopenia. While lymphocyte numbers gradually recover, there remain subtle but long-lasting changes to B and T cell populations years after radiation exposure....
2.
Singh T, Macintyre A, Burke T, Anderson J, Petzold E, Stover E, et al.
Front Immunol
. 2024 Dec;
15:1468871.
PMID: 39650666
Introduction: Dysregulated host cytokine responses to SARS-CoV-2 infection are a primary cause of progression to severe disease, whereas early neutralizing antibody responses are considered protective. However, there are gaps in...
3.
Liang K, Barnett K, Hsu M, Chou W, Bais S, Riebe K, et al.
Sci Immunol
. 2024 Jul;
9(97):eadn0178.
PMID: 38996010
Virus-induced cell death is a key contributor to COVID-19 pathology. Cell death induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is well studied in myeloid cells but less in...
4.
Malewana R, Stalls V, May A, Lu X, Martinez D, Schafer A, et al.
bioRxiv
. 2024 Jan;
PMID: 38187726
Immunization with mRNA or viral vectors encoding spike with diproline substitutions (S-2P) has provided protective immunity against severe COVID-19 disease. How immunization with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)...
5.
Wang C, Karlsson A, Oguin 3rd T, Macintyre A, Sempowski G, McCarthy K, et al.
Proc Natl Acad Sci U S A
. 2023 Oct;
120(44):e2306465120.
PMID: 37871214
Nucleic acid vaccines have shown promising results in the clinic against infectious diseases and cancers. To robustly improve the vaccine efficacy and safety, we developed an approach to increase the...
6.
Caradonna T, Ronsard L, Yousif A, Windsor I, Hecht R, Bracamonte-Moreno T, et al.
Cell Rep
. 2022 Nov;
41(6):111628.
PMID: 36351401
Pathogens evade host humoral responses by accumulating mutations in surface antigens. While variable, there are conserved regions that cannot mutate without compromising fitness. Antibodies targeting these conserved epitopes are often...
7.
Li D, Martinez D, Schafer A, Chen H, Barr M, Sutherland L, et al.
Nat Commun
. 2022 Oct;
13(1):6309.
PMID: 36274085
Coronavirus vaccines that are highly effective against current and anticipated SARS-CoV-2 variants are needed to control COVID-19. We previously reported a receptor-binding domain (RBD)-sortase A-conjugated ferritin nanoparticle (scNP) vaccine that...
8.
Wong S, Huang B, Hu X, Kim E, Kolb J, Padilla R, et al.
Cell Death Differ
. 2022 Oct;
30(3):855.
PMID: 36202991
No abstract available.
9.
Li D, Martinez D, Schafer A, Chen H, Barr M, Sutherland L, et al.
bioRxiv
. 2022 Feb;
PMID: 35118474
Coronavirus vaccines that are highly effective against SARS-CoV-2 variants are needed to control the current pandemic. We previously reported a receptor-binding domain (RBD) sortase A-conjugated ferritin nanoparticle (RBD-scNP) vaccine that...
10.
Heggestad J, Britton R, Kinnamon D, Wall S, Joh D, Hucknall A, et al.
Sci Adv
. 2021 Dec;
7(49):eabl7682.
PMID: 34860546
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants are concerning in the ongoing coronavirus disease 2019 (COVID-19) pandemic. Here, we developed a rapid test, termed CoVariant-SCAN, that detects neutralizing antibodies...